the patentability of biotechnological inventions: the european commission’s second 16c report
DESCRIPTION
Friday, 5th May 2006. The patentability of biotechnological inventions: The European Commission’s second 16c report. Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at R. Schuman University Strasbourg (France). WWW.ULYS.NET. Structure. I. Introduction - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/1.jpg)
The patentability of biotechnological inventions: The European Commission’s
second 16c report
Paul Van den BulckPartner at Ulys Law Firm (Brussels)
Lecturer at R. Schuman University Strasbourg (France)
Friday, 5th May 2006
WWW.ULYS.NET
![Page 2: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/2.jpg)
Structure
I. Introduction
II. Content of the second 16c report
(A) latest developments occurred since the publication of the first 16c report
(B) the scope of patents on sequences or partial sequences of genes which have been isolated from the human body
(C) the patentability of embryonic human stem cells and cell lines obtained from them
![Page 3: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/3.jpg)
I. Introduction
![Page 4: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/4.jpg)
Directive 98/44/EC of 6 July 1998 on the legal protection of biotechnological inventions
Article 16c of the Directive: “The Commission shall send the European Parliament and the Council […] annually as from the date specified in Article 15(1), a report on the development and implications of patent law in the field of biotechnology and genetic engineering.”
![Page 5: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/5.jpg)
the first 16c report (http://europa.eu.int/eur-lex/en/com/rpt/2002/com2002_0545en01.pdf) dealt with:
the implementation of the Directive in Europe; the compatibility of the Directive with the relevant international
agreements ; the patentability of inventions relating to plants and animals; the patentability of inventions relating to elements isolated from the
human body; exclusion from patentability of inventions whose commercial
exploitation would be contrary to ordre public or morality.
![Page 6: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/6.jpg)
the second 16c report of 14 July 2005 (http://www.europa.eu.int/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=en&numdoc=52005DC0312&model=guichett)
involvement of the Group of Experts and the European Group on Ethics
![Page 7: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/7.jpg)
II. The second 16c report
![Page 8: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/8.jpg)
A. latest developments occurred since the publication of the first 16c report
the European Commission draws the stateof progress regarding the transposition ofthe Directive into the national legislation of the EC Member States: 21 Member States have notified the Commission their legal instruments implementing the Directive
![Page 9: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/9.jpg)
Setting up of a group of Experts to advise the Commission on the preparation of 16c reports.
![Page 10: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/10.jpg)
The European Commission reports that the adoption of Council Regulation amending Regulation 2100/94 on Community plant variety rights in order to render Article 29 of Regulation 2100/94 and Article 12 of the Directive mutually compatible.
These provisions deal with cross-licenses on patent and plant variety rights.
![Page 11: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/11.jpg)
B. the scope of patents on (partial) sequences of genes which have been isolated from the human body The European Commission addresses the
question on whether patents on DNA sequences should be allowed according to:
the classical model of patent claim, i.e. the inventor claims an invention which covers possible future uses of that sequence; or
the “purpose-bound protection” model, i.e. a restriction of the patent so that only the specific use disclosed in the patent application can be claimed?
![Page 12: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/12.jpg)
Laws implementing Directive 98/44 in France and Germany provide for purpose-bound protection: France: Art. L 613-2-1, Code de la propriété
intellectuelle Germany: S. 1a (4), Patentgesetz
In the second 16c report, the European Commission does not take position on the validity of transposition of the Directive, by the Member States, according to the choice between classical and limited scope of protection for gene sequences.
![Page 13: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/13.jpg)
C. the patentability of human embryonic stem cells and cell lines obtained from them General context : patentability of human stem
cells and cell lines. Article 5 (2) of the Directive:
“An element isolated from the human body...including the sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of that element is identical to that of a natural element.”
![Page 14: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/14.jpg)
Article 5 (2) of the Directive: allows for the patentability of human stem
cells; and allows for the patentability of human stem cell
lines(if the invention is new, involves an inventivestep and is susceptible of industrial application)
![Page 15: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/15.jpg)
As regards to human embryonic stem cells, one has to distinguish: totipotent stem cells which are capable of
developing into a human being pluripotent stem cells which are not so
capable
![Page 16: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/16.jpg)
Article 5 (1) of the Directive:
“The human body, at the various stages of its formation and development, and the simple discovery of one of its elements... cannot constitute patentable inventions.”
totipotent stem cells = unpatentable (since they are capable of developing into a human being)
What about the patentability of pluripotent stem cells? According to the European Commisson: a more complex situation
![Page 17: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/17.jpg)
Article 6 of the Directive:1. Inventions shall be considered unpatentable
where their commercial exploitation would be contrary to ordre public or morality;
2. ...the following, in particular, shall be considered unpatentable: (...) (c) uses of human embryos for industrial or commercial purposes;...
![Page 18: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/18.jpg)
Article 6(2)c): does the unpatentability concerns (i) an embryo as a whole or (ii) every invention concerning embryonic stem cells? No consensus within the Group of Experts.
Importance of the interpretation of the concept of “embryo” in the national legislation of the Member States
![Page 19: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/19.jpg)
the European Commission refrains from giving a further definition or to provide for further harmonization in the area of Article 6(2)c)
the European Commission concludes that “there is no immediate answer to the question of the patentability of embryonic pluripotent stem cells.”
![Page 20: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/20.jpg)
‘EDINBURGH PATENT’- case :
Patent granted in December 1999
patent for ‘animal transgenic stem cells’
EPO Opposition Proceedings (July 2002):
amendment to exclude human embryonic stem cells
adopted broad interpretation of Rule 23(d)(c) (6(2)c of directive)
does this mean that human embryonic stem cells are unpatentable ?
The decision of the Board of Appeal is awaited (end 2006)
![Page 21: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/21.jpg)
TO BE CONTINUED……
![Page 22: The patentability of biotechnological inventions: The European Commission’s second 16c report](https://reader035.vdocuments.us/reader035/viewer/2022081519/56812be3550346895d905920/html5/thumbnails/22.jpg)
Paul Van den BulckPartner at Ulys Law Firm (Brussels)
Lecturer at R. Schuman University Strasbourg (France)
&Questions
Answers
WWW.ULYS.NET